Equities

Seed Co Ltd

7743:TYO

Seed Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)589.00
  • Today's Change4.00 / 0.68%
  • Shares traded33.70k
  • 1 Year change+0.51%
  • Beta1.0630
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Seed Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and sale of contact lenses, as well as the sale of contact lens care products and other products. The Contact Lens and Care Products segment sells contact lenses, care products, and related products. Contact lens products include hard lenses, soft lenses, disposable lenses, orthokeratology lenses, and related products such as optical instruments. Contact lens care products include preservatives, cleaning solutions, enzymatic cleaning solutions, chemical disinfectants, storage cases, and others. The other businesses include eyeglass frames, eyeglass fixtures, intraocular lenses, and others.

  • Revenue in JPY (TTM)32.05bn
  • Net income in JPY648.96m
  • Incorporated1957
  • Employees974.00
  • Location
    Seed Co LtdSanyo Yasuda Bldg.2-11, Kanda Nishiki-choCHIYODA-KU 101-0054JapanJPN
  • Phone+81 338131111
  • Websitehttps://www.seed.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Create Medic Co Ltd12.59bn154.02m9.54bn962.0058.310.601312.850.757916.9316.931,382.671,641.590.66021.743.8613,082,590.000.8083.000.95253.5343.5345.361.224.602.83--0.057663.222.103.11-68.06-25.530.66271.12
DVx Inc46.19bn397.59m10.75bn319.0026.111.1412.990.232738.1938.194,430.49875.082.0024.494.00144,803,700.001.724.044.149.8110.7112.240.86071.891.48--0.0032.014.374.418.481.80-2.355.46
OLBA Healthcare Holdings Inc117.02bn1.50bn12.60bn1.32k8.051.109.920.1077250.44250.4419,539.551,826.782.6616.204.3288,854,800.003.402.7112.139.7811.5811.061.280.91740.9764152.760.162732.162.330.5165-7.896.06-6.4211.84
JMS Co Ltd64.86bn204.00m13.21bn5.65k64.130.32813.430.20368.338.332,651.291,627.390.83862.673.7311,479,120.000.25091.730.35972.5622.4125.130.29912.021.071.840.37134.219.582.43-65.98-14.943.911.22
Techno Medica Co Ltd9.73bn1.23bn15.15bn225.0011.550.912311.261.56149.84149.841,190.251,896.310.58222.413.6343,247,240.007.386.598.357.6449.9248.1612.6712.035.27--0.0039.88-3.421.60-10.20-2.5418.515.92
HOSHI IRYO-SANKI CO., LTD14.59bn1.38bn16.96bn470.0011.290.94397.361.16441.64441.644,683.445,281.520.686823.495.7631,036,470.006.535.438.216.8948.6749.229.508.332.83--0.0017.697.895.7213.237.7710.738.45
Medius Holdings Co Ltd247.46bn1.14bn17.10bn2.29k14.860.90986.030.069151.9451.9411,254.21848.562.3317.024.37108,156,900.001.081.644.416.0212.1311.490.46220.58370.896268.940.589931.155.497.29-19.8015.0942.529.46
Daiken Medical Co Ltd9.65bn912.09m17.70bn188.0017.512.3115.751.8431.7531.75335.80240.850.87443.723.5951,314,050.008.277.1812.1210.4739.0542.969.459.251.52509.690.267673.266.991.25-14.32-6.79-20.77-0.9711
Seed Co Ltd32.05bn648.96m17.83bn974.0022.721.145.330.556325.9225.921,280.20514.910.7562.447.7632,903,220.001.431.572.542.7942.5542.591.892.120.613226.090.632447.176.101.91-127.39---34.239.86
Japan Medical Dynamic Marketing, INC.23.18bn1.27bn17.98bn488.0014.060.70096.200.775648.3048.30880.53968.740.76090.68154.15--4.296.514.927.5363.6966.975.638.882.11--0.055218.268.786.74-10.68-8.52-2.959.24
Japan Tissue Engineering Co., Ltd.2.51bn143.17m25.83bn215.00180.404.2593.1710.273.533.5361.91149.730.36253.534.26--2.06-4.722.37-5.3167.2457.305.69-16.385.85996.59----23.701.29119.63--30.22--
Data as of May 02 2024. Currency figures normalised to Seed Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

5.81%Per cent of shares held by top holders
HolderShares% Held
Rheos Capital Works, Inc. (Investment Management)as of 30 Sep 2022926.30k3.06%
Meiji Yasuda Asset Management Co. Ltd.as of 22 May 2023264.00k0.87%
Nomura Asset Management Co., Ltd.as of 29 Mar 2024162.20k0.54%
Daiwa Asset Management Co. Ltd.as of 29 Mar 2024130.20k0.43%
Dimensional Fund Advisors LPas of 04 Apr 2024127.90k0.42%
Nikko Asset Management Co., Ltd.as of 05 Apr 202477.20k0.26%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Apr 202432.70k0.11%
BlackRock Japan Co. Ltd.as of 04 Apr 202415.80k0.05%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 20 Apr 202313.00k0.04%
Acadian Asset Management LLCas of 31 Dec 20239.70k0.03%
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.